Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Disease Category: Pain
Location: United States, PA
Clinical Trial Details
Research Study Summary
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to
Evaluate the Safety and Efficacy of CEP-37247 Administered at Single Doses of 0.5,
1, 3, 6, 12, 20, or 30 mg by the Transforaminal Epidural Route for the Treatment of
Patients With Lumbosacral Radicular Pain Associated With Disk Herniation
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to
Evaluate the Safety and Efficacy of CEP-37247 Administered at Single Doses of 0.5, 1, 3, 6, 12, 20, or 30 mg by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation
Patient Inclusion Criteria:
- The patient is man or woman 18 through 70 years of age.
- Women of childbearing potential (ie, not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study, and have a negative pregnancy test at screening. Acceptable methods of contraception include barrier method with spermicide, abstinence, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method. NOTE: A woman will be considered surgically sterile if she has had a hysterectomy, bilateral salpingooophorectomy or bilateral oophorectomy, or hysterectomy with bilateral salpingooophorectomy. Tubal ligation without the use of an acceptable method of contraception will not be considered adequate birth control for this study.
- Over the 4 days prior to the randomization visit, the patient has a mean score greater than or equal to 5 (of 10) for “Average Pain Over the Past 24 Hours” for the pain in the affected leg as assessed by the NRS-11 captured in the electronic diaries. The patient must have valid (nonmissing) data for at least 3 out of the 4 days, and the mean score must be at least 5 without rounding.
- The patient has a current diagnosis of lumbosacral radicular pain. Pain must radiate into the leg in a dermatomal/myotomal distribution consistent with the diagnosis of lumbosacral radicular pain in the suspected involved nerve root. Based on history and medical records (if available), the duration of the current episode of pain must be between 6 and 52 weeks duration.
- Diagnosis must be confirmed by MRI (or existing computed tomography [CT] or MRI related to the symptoms present at screening) performed within 6 months prior to screening and demonstrating disk herniation at a location consistent with the clinical symptoms of radicular pain. Other incidental pathology is permitted as long as it is asymptomatic and believed not causal of the primary diagnosis of lumbosacral radicular pain at the specific spinal level as described below.
- The patient must have at least 1 of the following: a positive straight leg raise (L5-S1), positive femoral stretch test (L3-L4), or other positive test result upon physical examination that is consistent with the presence of nerve root irritation at the nerve root suspected to be involved in the diagnosed lumbosacral radicular pain at screening.
- Herniation must affect L3-L4, L4-L5, or L5-S1 and must be consistent with clinical presentation of the current episode of lumbosacral radicular pain as described above.
- Patients with significant or progressive sensory impairment or motor impairment (such as foot drop) must be assessed on a case-by-case basis by the investigator, and must in each case receive written approval of the Sponsor prior to randomization.
- There must be confirmation that the patient does not have an active tuberculosis infection at screening. The patient should have either a negative QuantiFERON®-TB Gold blood test or a negative tuberculin skin test (TST) result at screening; however, if QuantiFERON®-TB Gold test or TST is positive, a chest radiogram may be used to determine whether a patient has an active infection.
- The patient is willing to keep all analgesic medication and other therapy usage (such as physiotherapy, acupuncture, or transcutaneous electrical nerve stimulation [TENS]) stable or decreased during the study and use only the rescue pain medication as needed and as specified by the protocol.
- The patient is in good health (with the exception of the condition under study) as determined by a medical and psychiatric history, medical examination, ECG, serum chemistry, hematology, urinalysis, and serology.
- The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.
Patient Exclusion Criteria:
- The patient has a documented history of an allergic reaction (hives, rash, etc.) or a clinically significant intolerance to study drug or ingredients.
- The patient has a body mass index (BMI) greater than 40 kg/m2.
- The patient has an established history of a major psychiatric disorder, not controlled with medication or appears to have anxiety that would interfere with clinical pain scores or participation in the trial.
- The patient has clinically significant abnormalities in clinical chemistry, hematology or
urinalysis, including serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (AST) or serum glutamic-pyruvic transaminase/alanine aminotransferase (ALT) greater than or equal to 3 times the upper limit of the reference range or an estimated glomerular filtration rate (eGFR) less than or equal to 30 mL/min/1.73 m2 (Modification of Diet in Renal Disease [MDRD] study formula) at screening.
- The patient has received an intra-epidural steroid injection for the treatment of the current episode of sciatica during the last 3 months prior to screening.
- The patient has significant pain unrelated to the disk herniation that would significantly compromise assessment of the radicular back and leg pain related to the disk herniation.
- The patient has radiologic evidence of disk herniation at more than 1 spinal level, and clinical evidence of lumbosacral radicular pain at more than 1 spinal nerve corresponding to the levels of the multiple disk herniations.
- The patient has received any investigational drug within 30 days prior to screening, or is scheduled to receive an investigational drug other than blinded study drug during the course of this study.
- The patient has had lumbar or sacral back surgery related to the specific disk that is the cause of the radicular pain upon presentation to the study, or currently plans to undergo spine surgical intervention while in the study.
- The patient has received epidural corticosteroid injections in the back within 3 months of screening.
- The patient is involved in an ongoing worker’s compensation claim, disability claim, or litigation related to any pain problem.
- The patient has any active infection that is not self-limiting and not resolved prior to study drug administration.
- The patient has a history of malignancy or evidence of malignancy or lymphoproliferative or neoplastic disease with the exception of successfully treated basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia within 5 years of the screening visit.
- The patient has a history of systemic fungal infection.
- The patient has a history of opportunistic infection within 3 months prior to screening.
- The patient has a history of known or suspected chronic infection, tuberculosis, hepatitis B virus (HBV), hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV). NOTE: Although HIV testing will not be performed, the investigator will review all medical history (including medication history), and patients found to be HIV positive based on medical review are to be excluded from the study.
- The patient has a history of any demyelinating disease, including multiple sclerosis and optic neuritis.
- The patient has used anti-tumor necrosis factor (TNF) receptor medication (anakinra [KINERET®, Biovitrum]) or anti-TNF medication (etanercept [ENBREL®, Amgen Inc.], infliximab [REMICADE®, Centocor Ortho Biotech Inc.], or adalimumab [HUMIRA®, Abbott Laboratories], or any experimental TNF inhibitor) within the past year.
- The patient has a planned joint replacement surgery or a history of infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis if that prosthesis has not been removed or replaced.
- The patient has been given live vaccines within 14 days of study drug administration.
- The patient has severe spinal stenosis or spondylolisthesis (grade 2 or higher).
- The patient has coagulopathy.
- The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.).
- The patient has a history of diabetic neuropathy or peripheral neuropathy in the lower extremities.
- The patient has a history of any condition (not otherwise specified) known to be amenable to TNF inhibitors (eg, Crohns disease).
- The patient has a known allergy or idiosyncratic (atopic) reaction to contrast agent, local anesthetic, study drug, any ingredient listed as being present in a study formulation, or any other pain management compound likely to be prescribed in the study, including their metabolites (if applicable) or any ingredient listed as being present in their formulations.
- The patient has any clinically significant medical condition (treated or untreated), which in the opinion of the investigator would likely interfere with participation in the study or affect the clinical course of sciatica (beyond the disk herniation)
To Learn more
Both Male and Female
Date Last Changed:
July 18, 2013
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these